検索結果一覧

一般口演 / Oral Session

一般口演 81 (Oral Session 81) :CML:中規模臨床
 
日程
2013年10月13日(日)
時間
09:45 - 10:45
会場
第7会場 / Room No.7 (ロイトン札幌 2F リージェント)
座長・司会
永井 正 (Tadashi Nagai):1
1:自治医科大学 内科学講座血液学部門

前へ戻る


Sustained molecular response with IFN after imatinib discontinuation in patients with CML

演題番号 : OS-3-46

臼杵 憲祐 (Kensuke Usuki):1、遊佐 希 (Nozomi Yusa):2、半下石 明 (Akira Hangaishi):1、関根 理恵子 (Rieko Sekine):3、鈴木 憲史 (Kenshi Suzuki):3、木村 晋也 (Shinya Kimura):4、東條 有伸 (Arinobu Tojo):5

1:Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan、2:Dept. of Applied Genomics, Institute of Medical Science Hospital, The University of Tokyo, Japan、3:Department of Hematology, Japanese Red Cross Medical Center, Japan、4:Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Saga University, Japan、5:The Institute of Medical Science, The University of Tokyo, Japan

Sustained molecular response with IFN after imatinib discontinuation in patients with CML

Early cytogenetic response predicts outcome for CML patients treated with tyrosine kinase inhibitors

演題番号 : OS-3-47

吉田 近思 (Chikashi Yoshida):1、工藤 大輔 (Daisuke Kudo):2、太田 育代 (Ikuyo Ota):1、坂本 竜弘 (Tatsuhiro Sakamoto):2、桂 行孝 (Yukitaka Katsura):1、品川 篤司 (Atsushi Shinagawa):2、米野 琢哉 (Takuya Komeno):1

1:Department of Hematology, National Hospital Organization Mito Medical Center、2:Hitachi General Hospital

Early cytogenetic response predicts outcome for CML patients treated with tyrosine kinase inhibitors

Nilotinb switching from imatinib is effective to induce complete molecular response in CML-CP

演題番号 : OS-3-48

岡田 昌也 (Masaya Okada):1、藤盛 好啓 (Yoshihiro Fujimori):1、高塚 広行 (Hiroyuki Takatsuka):2、内田 三千彦 (Michihiko Uchida):3、渡邊 光正 (Mitsumasa Watanabe):3、永井 朝子 (Tomoko Nagai):4、田端 理英 (Rie Tabata):4、松下 章子 (Akiko Matsushita):5、小高 泰一 (Taiichi Kodaka):6、三澤 眞人 (Mahito Misawa):7、足立 陽子 (Yoko Adachi):8、岡本 隆弘 (Takahiro Okamoto):9、高蓋 寿朗 (Toshiro Takafuta):10、小川 啓恭 (Hiroyasu Ogawa):1

1:Division of Hematology, Department of Internal Medicine,Hyogo College of Medicine,Japan、2:Department of Internal Medicine,Amagasaki Central Hospital,Japan、3:Department of Hematology,Hyogo Prefectural Amagasaki Hospital,Japan、4:Department of Internal Medicine,Hyogo Prefectural Tsukaguchi Hospital,Japan、5:Department of Hematology,Kobe City Medical Center General Hospital,Japan、6:Department of Hematology,Shinko Hospital,Japan、7:Department of Internal Medicine,Ako Hospital,Japan、8:Department of Internal Medicine,Kobe Central Hospital of Social Insurance,Japan、9:Department of Hematology,Takarazuka Municipal Hospital,Japan、10:Department of Respiratory Medicine, Nishi-Kobe Medical Center,Japan

Nilotinb switching from imatinib is effective to induce complete molecular response in CML-CP

Phase I/II trial of imatinib dose reduction study for CML-CP patients: The JALSG CML-DR1 study

演題番号 : OS-3-49

石川 真穂 (Maho Ishikawa):1、大西 一功 (Kazunori Ohnishi):2、宮村 耕一 (Koichi Miyamura):3、青山 泰孝 (Yasutaka Aoyama):4、魚嶋 伸彦 (Nobuhiko Uoshima):5、直江 知樹 (Tomoki Naoe):6

1:Dept. Hematology, Saitama Medical University International Medical Center, Japan、2:Oncology Center, Hamamatsu University School of Medicine, Japan、3:Hematology Division, Japanese Red Cross Nagoya First Hospital, Japan、4:Division of Hematology, Seichokai Fuchu Hospital, Japan、5:Dept. Hematology, Matsushita Memorial Hospital, Japan、6:Dept. Hematology and Oncology, Nagoya University Graduate School of Medicine, Japan

Phase I/II trial of imatinib dose reduction study for CML-CP patients: The JALSG CML-DR1 study

Clinical performance study of a BCR-ABL1 kit which reports BCR-ABL1 mRNA on an international scale

演題番号 : OS-3-50

日野 雅之 (Masayuki Hino):1、宮村 耕一 (Koichi Miyamura):2、岡本 真一郎 (Shinichiro Okamoto):3、薄井 紀子 (Noriko Usui):4、赤司 浩一 (Koichi Akashi):5、中世古 知昭 (Chiaki Nakaseko):6、高橋 直人 (Naoto Takahashi):7、中谷 中 (Kaname Nakatani):8、登 勉 (Tsutomu Nobori):9、直江 知樹 (Tomoki Naoe):10

1:Department of Hematology, Osaka City Univ., Japan、2:Department of Hematology, Japanese Red Cross Nagoya First Hospital, Japan、3:Division of Hematology, Keio Univ., Japan、4:Division of Clinical Oncology/Hematology, Jikei Univ. Dai-san Hospital, Japan、5:Department of Medicine and Biosystemic Science, Kyushu Univ., Japan、6:Department of Hematology, Chiba Univ., Japan、7:Department of Hematology, Akita Univ., Japan、8:Division of Personalized Medicine, Mie Univ., Japan、9:Department of Molecular and Laboratory Medicine, Mie Univ., Japan、10:Department of Hematology and Oncology, Nagoya Univ., Japan

Clinical performance study of a BCR-ABL1 kit which reports BCR-ABL1 mRNA on an international scale